Israeli Researchers Find Immune Cells Aiding Tumor Development

Researchers from the Tel Aviv University have discovered that some immune cells in the body of a patient with cancer stop fighting cancer after a time and instead begin protecting the tumor. This breakthrough by the Israeli researchers could enhance the efficacy of treatments for cancer, in particular brain cancer.

The researchers’ findings were reported in the “Cell Reports” journal.

The researchers found that these white blood cells, known as neutrophils, are effective in killing fungi and bacteria. Normally, these cells initially fight against glioblastoma before they stop and instead begin to protect the tumor, helping it grow.

Glioblastoma is one of the deadliest and most common types of brain cancer. It has an average life expectancy of one year to 15 months. This aggressive cancer usually occurs in the spinal cord or the brain and develops from cells known as astrocytes, which usually support nerve cells. While it may develop at any age, the cancer mostly develops in older individuals. Glioblastoma causes seizures, vomiting, nausea and headaches.

In an interview, lead study researcher Dr. Dinorah Friedmann-Morvinski stated that the immune cells eliminated tumor cells while also recruiting other cells such as T-cells to help fight the cancer, noting that it was during this stage that they began guarding the tumor, which allowed it to grow more.

Friedmann-Morvinski explained that the neutrophils also secreted proteins that aided in the development of the tumors, adding that the now procancerous cells aggravated the damage that the tumor caused. The researchers made this discovery after they observed mice with glioblastoma. They then conducted an analysis of sequencing data from a number of glioblastoma patients in order to verify their hypothesis, which afforded them insight into how the disease progressed in every patient.

Friedmann-Morvinski forecasts that their research will likely pave the way to improving the efficacy of glioblastoma treatments. She explains that this information can be used to develop medications that may prevent the cells from becoming precancerous and protecting the tumor or blocking their effect altogether. The research team includes Prerna Magod, a PhD student who is currently focused on developing such medications.

Friedmann-Morvinski notes that this discovery will also allow researchers to find ways to keep the cells on the “good” side while also increasing the chances of treatments working effectively without the presence of cells that counteract its efficacy. She adds that this makes their findings as well as their effort to identify medications significant.

Fortunately, other companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also engaged in looking for novel remedies to some of the most malignant forms of brain cancer. Patients can look forward to more efficacious treatments in the years to come.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050